Cinctive Capital Management LP Sells 65,510 Shares of Vera Therapeutics, Inc. $VERA

Cinctive Capital Management LP trimmed its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA) by 40.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 96,573 shares of the company’s stock after selling 65,510 shares during the period. Cinctive Capital Management LP owned approximately 0.15% of Vera Therapeutics worth $2,806,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Capricorn Fund Managers Ltd bought a new position in shares of Vera Therapeutics in the third quarter worth $13,097,000. Swedbank AB bought a new stake in shares of Vera Therapeutics during the 3rd quarter valued at $1,453,000. Squarepoint Ops LLC raised its stake in shares of Vera Therapeutics by 232.0% during the 2nd quarter. Squarepoint Ops LLC now owns 57,519 shares of the company’s stock valued at $1,355,000 after purchasing an additional 40,196 shares during the period. Bollard Group LLC purchased a new stake in Vera Therapeutics during the 2nd quarter worth about $1,509,000. Finally, SG Americas Securities LLC bought a new position in Vera Therapeutics in the 3rd quarter worth about $911,000. Institutional investors own 99.21% of the company’s stock.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, insider Laurence Matthew Skelton sold 1,582 shares of the business’s stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $66,412.36. Following the completion of the transaction, the insider owned 64,218 shares of the company’s stock, valued at $2,695,871.64. The trade was a 2.40% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marshall Fordyce sold 16,925 shares of the firm’s stock in a transaction on Monday, February 23rd. The shares were sold at an average price of $41.98, for a total transaction of $710,511.50. Following the sale, the chief executive officer owned 257,163 shares in the company, valued at approximately $10,795,702.74. This trade represents a 6.18% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 33,490 shares of company stock valued at $1,405,910 over the last quarter. Company insiders own 16.30% of the company’s stock.

Vera Therapeutics Stock Performance

NASDAQ:VERA opened at $39.96 on Monday. The stock has a market cap of $2.80 billion, a P/E ratio of -8.58 and a beta of 1.17. The company has a quick ratio of 13.64, a current ratio of 13.64 and a debt-to-equity ratio of 0.12. The business’s 50-day moving average price is $43.81 and its two-hundred day moving average price is $36.96. Vera Therapeutics, Inc. has a twelve month low of $18.53 and a twelve month high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($1.34) by ($0.05). During the same period in the prior year, the firm earned ($0.72) earnings per share. As a group, equities analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have weighed in on VERA shares. JPMorgan Chase & Co. reduced their target price on Vera Therapeutics from $99.00 to $96.00 and set an “overweight” rating for the company in a report on Friday, December 19th. TD Cowen restated a “buy” rating on shares of Vera Therapeutics in a research report on Friday, December 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Wednesday, January 21st. Evercore upped their target price on shares of Vera Therapeutics from $75.00 to $97.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Finally, Pivotal Research set a $73.00 target price on shares of Vera Therapeutics in a research note on Friday, December 5th. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $81.45.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.